| Primary |
| Immunosuppression |
21.9% |
| Renal Transplant |
18.4% |
| Liver Transplant |
12.5% |
| Intestinal Transplant |
9.6% |
| Prophylaxis Against Transplant Rejection |
6.1% |
| Foetal Exposure During Pregnancy |
5.4% |
| Lung Transplant |
4.9% |
| Prophylaxis Against Graft Versus Host Disease |
3.3% |
| Heart Transplant |
2.5% |
| Prophylaxis |
2.5% |
| Product Used For Unknown Indication |
1.9% |
| Graft Versus Host Disease |
1.8% |
| Immunosuppressant Drug Therapy |
1.6% |
| Transplant |
1.6% |
| Bone Marrow Transplant |
1.2% |
| Keratoplasty |
1.1% |
| Pancreas Islet Cell Transplant |
1.1% |
| Chemotherapy |
0.9% |
| Hepatitis C |
0.9% |
| Hiv Infection |
0.9% |
|
| Off Label Use |
25.4% |
| Transplant Rejection |
10.2% |
| Premature Delivery |
8.5% |
| Renal Failure Chronic |
8.5% |
| Premature Baby |
7.6% |
| Urinary Tract Infection |
4.2% |
| Kidney Transplant Rejection |
3.4% |
| Neoplasm Malignant |
3.4% |
| Post Transplant Lymphoproliferative Disorder |
3.4% |
| Renal Failure |
3.4% |
| Tremor |
3.4% |
| Food Allergy |
2.5% |
| Hepatocellular Carcinoma |
2.5% |
| Hyperinsulinaemia |
2.5% |
| Hypertension |
2.5% |
| Foetal Death |
1.7% |
| Graft Versus Host Disease |
1.7% |
| Hypoxic-ischaemic Encephalopathy |
1.7% |
| Multi-organ Failure |
1.7% |
| Polyomavirus-associated Nephropathy |
1.7% |
|
| Secondary |
| Prophylaxis Against Transplant Rejection |
24.9% |
| Prophylaxis |
12.5% |
| Immunosuppression |
7.0% |
| Renal Transplant |
6.2% |
| Liver Transplant |
4.9% |
| Nausea |
4.8% |
| Intestinal Transplant |
4.0% |
| Pain |
3.7% |
| Hiv Infection |
3.4% |
| Antifungal Prophylaxis |
3.3% |
| Product Used For Unknown Indication |
3.3% |
| Pyrexia |
3.0% |
| Prophylaxis Against Graft Versus Host Disease |
2.9% |
| Rash |
2.9% |
| Vomiting |
2.9% |
| Constipation |
2.3% |
| Antibiotic Prophylaxis |
2.2% |
| Antiviral Prophylaxis |
1.9% |
| Graft Versus Host Disease |
1.9% |
| Premedication |
1.9% |
|
| Urinary Tract Infection |
28.0% |
| Off Label Use |
17.1% |
| Post Procedural Myocardial Infarction |
8.5% |
| Renal Failure Chronic |
7.3% |
| Graft Versus Host Disease In Intestine |
6.1% |
| Graft Versus Host Disease |
4.9% |
| Haemorrhage Intracranial |
4.9% |
| Multi-organ Failure |
2.4% |
| Pericarditis |
2.4% |
| Post Transplant Lymphoproliferative Disorder |
2.4% |
| Pyrexia |
2.4% |
| Toxicity To Various Agents |
2.4% |
| Transplant Rejection |
2.4% |
| Cytomegalovirus Infection |
1.2% |
| Graft Versus Host Disease In Skin |
1.2% |
| Liver Disorder |
1.2% |
| Lung Neoplasm Malignant |
1.2% |
| Premature Delivery |
1.2% |
| Renal Failure |
1.2% |
| Self Injurious Behaviour |
1.2% |
|
| Concomitant |
| Product Used For Unknown Indication |
90.0% |
| Bronchopulmonary Aspergillosis |
2.5% |
| Disseminated Cryptococcosis |
2.5% |
| Scan Myocardial Perfusion |
2.5% |
| Urinary Incontinence |
2.5% |
|
| Drug Ineffective |
25.0% |
| Nausea |
25.0% |
| Tachycardia |
25.0% |
| Vomiting |
25.0% |
|
| Interacting |
|
| Transplant Rejection |
100.0% |
|
